Response to Office Action dated March 25, 2009

Atty Docket: 102790-211

Page 2

II. CLAIMS

In the Claims:

- 1.(Currently Amended) A recombinant cellular system, comprising an animal host cell, comprising the following recombinant proteins:
 - a recombinant specific G protein-coupled receptor, and
 - a recombinant CNGA2 Ca2+ permeable channel and
- a substance selected from the group consisting of connexins, a cyclase that is harmonised with the specific G protein-coupled receptor and a recombinant G-protein that is harmonised with the specific G protein-coupled receptor,

where the recombinant specific G protein-coupled receptor, is selected from the group consisting of pheromone receptors and the olfactory receptors, type A guanylyl-cyclases, and type G guanylyl-cyclases.

- 2. (Currently Amended) The recombinant cellular system according to claim 1, <u>further comprising</u> where the substance is a recombinant protein selected from the group of connexins.
- 3.(Previously Presented) The recombinant cellular system according to claim 1, wherein the recombinant specific G protein-coupled receptor is selected from type A guanylyl-cyclases and type G guanylyl-cyclases.
- 4.(Currently Amended) The recombinant cellular system according to claim 1 further comprising where the substance is a cyclase that is harmonised with the specific G protein-coupled receptor.
- 5.(Previously Presented) The recombinant cellular system according to claim 1, wherein the recombinant specific G

Response to Office Action dated March 25, 2009

Atty Docket: 102790-211

Page 3

protein-coupled receptor is selected from: pheromone receptors, hormone receptors and the olfactory receptors.

- 6.(Currently Amended) The recombinant cellular system according to claim 1 further comprising where the substance is a recombinant G-protein that is harmonised with the specific G protein-coupled receptor.
- 7.(Previously Presented) The recombinant cellular system according to claim 1 wherein the animal host cell is selected from murine cell lines and human cell lines.
- 8.(Previously Presented) The recombinant cellular system according to claim 1, wherein the cellular system comprises a potential recombinant specific G protein-coupled receptor.
- 9.(Previously Presented) The recombinant cellular system according to claim 7, selected from the group of cellular systems comprising: HeLaCx43/CNGA2/01fr49; HeLa-Cx43/CNGA2/G-alpha-olf; HeLa-Cx43/CNGA2/G-alpha-olf/Olfr 49; HeLa-Cx43/CNGA2/G-alpha-olf/Olfr41; HeLa-Cx43/CNGA2/G-alpha-olf/Olfr 6 and HeLa-Cx43/CNGA2/G-alpha-olf/OR1A1.
- 10.(Previously Presented) The recombinant cellular system according to claim 1, wherein the recombinant proteins are present stably.
- 11.(Previously Presented) The recombinant cellular system HeLa- Cx43/CNGA2/G-alpha-olf, as deposited on April 20, 2004 at the DSMZ Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH in Mascheroder Weg lb, D38124 Braunschweig with the deposit number DSM ACC2649.
- 12.(Previously Presented) A method for producing a recombinant cellular system, comprising the steps of:

Response to Office Action dated March 25, 2009

Atty Docket: 102790-211

Page 4

- providing of an animal host cell,
- introducing a recombinant specific G protein-coupled
 receptor or a potential recombinant specific G protein-coupled
 receptor, and
 - introducing the recombinant CNGA2 Ca2+ permeable channel.
- 13.(Previously Presented) The method according to claim 12, further comprising the step of:
- introducing a recombinant protein from the group of the connexins.
- 14.(Previously Presented) The method according to claim 12, further comprising the step of:
- introducing a cyclase that is harmonised with the specific G protein-coupled receptor.
- 15.(Previously Presented) The method according to claim 12 further comprising the step of:
- introducing of a recombinant G-protein that is harmonised with the specific G protein-coupled receptor.
- 16.(Previously Presented) The method according to claim 12, wherein the introducing method step is selected from: (Ca2+-phosphate-)transfection, lipofection or electroporation,

optionally followed by the step of integration into the genome with the aid of a recombinase or antibiotic-selection cloning, or the step of transduction.

- 17. (Previously Presented) The method for identifying receptor activating substances, comprising the method steps of providing a recombinant cellular system according to claim 1,
 - contacting the cellular system with a potential G

Response to Office Action dated March 25, 2009

Atty Docket: 102790-211

Page 5

protein-coupled receptor activating substance, and

 $\,$ - measuring the activation or inhibition of the Ca2+ influx into the cellular system cell.

- 18.(Previously Presented) The method according to claim 17, wherein the potential G protein-coupled receptor inducing substance is selected from odorants, pheromones, and hormones.
- 19.(Previously Presented) The method according to claim 17, wherein the measuring of the Ca2+ influx into the cell includes: loading of the cell with Fura-2-AM or Fluo-4-AM, and measuring the emission-wavelength at 515 nm.
- 20.(Previously Presented) The method according to claim 17, wherein the cellular system is pre-treated with an enhancer.
- 21. (Previously Presented) A method for producing a pharmaceutical composition, comprising the steps of:
 - performing a method according to claim 17, and
- formulating the obtained G protein-coupled receptor inducing substance with auxiliary agents and additives.
- 22. (Previously Presented) A method for identifying of G protein-coupled receptors, comprising the steps of:
- providing a recombinant cellular system according to claim 8,
- contacting of the cellular system with a receptoractivating substance or presumably receptor-activating substance, and
- measuring the activation or inhibition of the Ca2+ influx into the cell.
 - 23. (Previously Presented) The method according to claim 17,

Response to Office Action dated March 25, 2009

Atty Docket: 102790-211

Page 6

wherein the method is performed in a high-throughput-environment.

- 24. (Cancelled)
- 25. (Cancelled)
- 26.(New) The recombinant cellular system of claim 1 where the G protein-coupled receptor is selected from the group consisting of OR1A1, OR1A2, Olfr43, Olfr49, MOR261-10, MOR267-1, LOC31758, Olfr41 and Olf6 and the connexin is selected from the group consisting of Cx43 and Cx26.
- 27. (New) The recombinant cellular system of claim 9 where the cellular system is HeLa-Cx43/CNGA2/G-alpha-olf.